Philip Morris in talks to reunite with Altria – Reuters
August 27, 2019A top Lowe’s executive apologized Tuesday, after saying a DeWalt power drill was perfect for “Hispanic pros with smaller hands.”
Uber and Lyft’s driver take rates higher than they say: Jalopnik – INSIDER
August 27, 2019The car-news site Jalopnik asked Uber and Lyft drivers to send in their receipts in an effort to analyze how big of a cut the companies take.
Johnson & Johnson ordered to pay $572M for fuelling Oklahoma’s opioid crisis – CBC News: The National
August 27, 2019An Oklahoma judge has found Johnson & Johnson and its subsidiaries helped fuel the state’s opioid drug crisis and ordered the consumer products giant to pay …
Warren Buffett’s Biggest Blunder Has Now Cost Him $16 Billion – Motley Fool
August 27, 2019Even the world’s greatest buy-and-hold investor can make mistakes.
Lyft stock rallies on new profitability prediction – MarketWatch
August 27, 2019Shares of ride-hailing app Lyft Inc. got a boost Monday after analysts predicted the company could be profitable sooner than expected. Lyft shares jumped…
‘Ridiculous at best’: Chinese state media give their take on Trump and the tariff war – CNBC
August 27, 2019China’s state media is putting up a brave front as the country’s trade war with the U.S. escalated sharply over the weekend.
Top China Trade Negotiator Calls for Calm as Trump Tensions Grow – Investing.com
August 27, 2019On August 26, Amgen (AMGN) announced the purchase of leading immunology drug Otezla from Celgene (CELG) for a cash consideration of $13.4 billion.
Democrats need a China strategy to replace Trump’s aggressive policy – Nikkei Asian Review
August 27, 2019US must unite at home before it can realistically face up to Beijing
Top China Trade Negotiator Calls for Calm as Trump Tensions Grow – Investing.com
August 27, 2019VMware debuted its Tanzu and Project Pacific products so coders can build and run Kubernetes-powered apps.
Amgen and Celgene’s Otezla Deal: Key Highlights – Market Realist
August 27, 2019On August 26, Amgen (AMGN) announced the purchase of leading immunology drug Otezla from Celgene (CELG) for a cash consideration of $13.4 billion.
